nuchal translucency measurement

nuchal translucency measurement

(trăns-loos′ĕn-sē)
Intrauterine ultrasonography of the nape of the fetal neck, measured in the first trimester of pregnancy. Abnormal thickening of this part of the body has been associated with a variety of congenital, chromosomal diseases.
References in periodicals archive ?
Also, NTD's first trimester non-invasive prenatal screening test for Down Syndrome is the only high sensitivity screen that uses the free Beta hCG biomarker, along with PAPP-A and Nuchal Translucency measurement, in assessing risk for Down syndrome.
Standard aneuploidy screening included assays of first- or second-trimester serum biomarkers with or without fetal nuchal translucency measurement.
Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and fetal outcome.
The examination was carried out by 4 doctors trained and certified in nuchal translucency measurement.
Abnormal first-trimester Doppler findings also appear to predict Down syndrome and other adverse outcomes independently of a normal nuchal translucency measurement.
Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
The First and Second Trimester Evaluation of Risk (FASTER) trial involved about 38,000 pregnant women at 15 centers who underwent combined first-trimester screening with nuchal translucency measurement and serum testing for the biochemical markers pregnancy-associated plasma protein A (PAPP-A) and free [beta]-HCG.
NEW ORLEANS -- First-trimester aneuploid screening using maternal age, biochemistry, and nuchal translucency measurement is "possible, accurate, and reliable," and should be more widely adopted, Dr.
When Integrated screening and Sequential screening test results include a fetal ultrasound nuchal translucency measurement, the highest Down syndrome detection rates are achieved and fewer false positives are experienced than with current first- or second-trimester screening.
Ductus venosus studies in foetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and foetal outcome.
Limitations of using first-trimester nuchal translucency measurement in routine screening for major congenital heart defects.
First-trimester nuchal translucency measurement and echocardiography at 16 to 18 weeks of gestation in prenatal detection for trisomy 18.